These dividend stocks are built to last years and pay out regularly to boost your retirement income.
News & Analysis: Allergan
With this final regulatory sign-off, the deal between these two pharmaceutical giants should close very soon.
Is it possible to have both growth and safety in this market?
The blockbuster pharmaceutical deal has had its share of detractors.
It's the first time this type of gene-editing treatment has been tested on a human.
The pharmaceutical giant stands accused of making false and misleading product comparisons.
The groups are worried about reduced competition if the merger goes through.
It's all about the lips with the soon-to-be-acquired company's latest advertising push.
Despite Humira's declining international sales, AbbVie is still worth considering.
The drugmaker delivered solid top- and bottom-line improvement as it awaited the closing of its acquisition by AbbVie.